Skip to main content
Contact Us
Subscribe
E-Edition
42°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
20.62
+0.36 (+1.80%)
Streaming Delayed Price
Updated: 10:58 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicycle Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
June 23, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
June 13, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics's Return On Capital Employed Insights
May 17, 2023
Via
Benzinga
Bicycle Therapeutics PLC (NASDAQ: BCYC) Making Surprising Moves in Friday Session
May 12, 2023
Via
Investor Brand Network
14 Analysts Have This to Say About Bicycle Therapeutics
May 11, 2023
Via
Benzinga
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
May 11, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
May 10, 2023
From
Bayer
Via
Business Wire
Recap: Bicycle Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Analyst Ratings for Bicycle Therapeutics
April 18, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics
March 01, 2023
Via
Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
November 23, 2022
Via
Benzinga
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
May 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
April 14, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
April 03, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
March 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Recap: Bicycle Therapeutics Q3 Earnings
November 03, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
February 14, 2023
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
January 11, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
January 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 10, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.